GENOMIC_CHANGE	GENOME_VERSION	VCF_SAMPLE_ID	SYMBOL	CONSEQUENCE	BM_CLINICAL_SIGNIFICANCE	BM_EVIDENCE_LEVEL	BM_EVIDENCE_TYPE	BM_EVIDENCE_DIRECTION	BM_DISEASE_NAME	BM_DRUG_NAMES	BM_RATING	BM_CITATION	TIER	TIER_DESCRIPTION
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Resistance or Non-Response	B: Clinical evidence	Predictive	Supports	Colorectal Cancer	Cetuximab, Panitumumab	3	Sartore-Bianchi et al., 2009, Cancer Res.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Poor Outcome	B: Clinical evidence	Prognostic	Supports	Colorectal Cancer	NA	3	Sartore-Bianchi et al., 2009, Cancer Res.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	C: Case study	Predictive	Supports	Her2-receptor Positive Breast Cancer	Everolimus, Fulvestrant	2	Sun et al., 2016, Onco Targets Ther	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Head And Neck Cancer	BYL719 (Alpelisib)	1	Keam et al., 2015, Anticancer Res.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Head And Neck Cancer	BEZ235 (NVP-BEZ235, Dactolisib)	1	Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Head And Neck Cancer	Cetuximab, BEZ235 (NVP-BEZ235, Dactolisib)	2	Lui et al., 2013, Cancer Discov	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Head And Neck Squamous Cell Carcinoma	Taselisib (GDC-0032)	2	Zumsteg et al., 2016, Clin. Cancer Res.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Head And Neck Cancer	BEZ235 (NVP-BEZ235, Dactolisib)	2	Lui et al., 2013, Cancer Discov	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Lung Adenocarcinoma	BEZ235 (NVP-BEZ235, Dactolisib)	3	Engelman et al., 2008, Nat. Med.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Her2-receptor Positive Breast Cancer	AZD5363, Trastuzumab	3	Davies et al., 2012, Mol. Cancer Ther.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Her2-receptor Positive Breast Cancer	AZD5363, Lapatinib	3	Davies et al., 2012, Mol. Cancer Ther.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Thyroid Cancer	Perifosine, Temsirolimus	3	Liu et al., 2009, Cancer Res.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Sensitivity	D: Preclinical evidence	Predictive	Supports	Breast Cancer	CH5132799	4	Tanaka et al., 2011, Clin. Cancer Res.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
g.chr3:178952085:A>G	GRCh37	tumor_sample.BRCA	PIK3CA	missense_variant	Resistance or Non-Response	B: Clinical evidence	Predictive	Supports	Colorectal Cancer	Cetuximab	3	De Roock et al., 2010, Lancet Oncol.	TIER 1	Clinical biomarker - prognostic/diagnostic/drug sensitivity/resistance
